Coherus Oncology, Inc.
$1.99
▼
-0.57%
2026-04-21 06:02:00
www.coherus.com
NGM: CHRS
Explore Coherus Oncology, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$295.28 M
Current Price
$1.99
52W High / Low
$2.62 / $0.71
Stock P/E
1.76
Book Value
$0.5
Dividend Yield
—
ROCE
-155.52%
ROE
-473.47%
Face Value
—
EPS
$-1.56
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
147
Beta
1.04
Debt / Equity
89.1
Current Ratio
1.47
Quick Ratio
1.43
Forward P/E
-2.07
Price / Sales
5.97
Enterprise Value
$134.05 M
EV / EBITDA
-0.78
EV / Revenue
3.18
Rating
Strong Buy
Target Price
$6.75
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Nuvation Bio Inc. | $5.12 | — | $1.77 B | — | -41.57% | -53.18% | $9.75 / $1.57 | $0.88 |
| 2. | Vistagen Therapeutics, Inc. | $0.61 | — | $24.12 M | — | -78.03% | -1.02% | $5.14 / $0.43 | $1.28 |
| 3. | Shattuck Labs, Inc. | $7.88 | — | $538.88 M | — | -61.34% | -60.25% | $7.68 / $0.71 | $1.3 |
| 4. | Wave Life Sciences Ltd. | $7.58 | — | $1.43 B | — | -39.63% | -54.97% | $21.73 / $5.02 | $2.76 |
| 5. | Tectonic Therapeutic, Inc. | $28.76 | — | $554.1 M | — | -33.43% | -37.82% | $36.03 / $14.39 | $13.41 |
| 6. | Moderna, Inc. | $55.11 | — | $21.94 B | — | -29.7% | -28.87% | $59.55 / $22.28 | $21.95 |
| 7. | Vanda Pharmaceuticals Inc. | $6.99 | — | $417.3 M | — | -43.97% | -50.93% | $9.94 / $3.81 | $5.54 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 12.75 M | 11.57 M | 10.25 M | 7.6 M | 54.14 M | — |
| Operating Profit | -45.88 M | -44.33 M | -45.49 M | -45.44 M | -42.25 M | — |
| Net Profit | -37.64 M | -35.53 M | 297.77 M | -56.57 M | -50.7 M | — |
| EPS in Rs | -0.25 | -0.24 | 1.99 | -0.38 | -0.34 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 42.17 M | 26.39 M | 257.24 M | 211.04 M |
| Operating Profit | -181.13 M | -199.65 M | -203.2 M | -256.88 M |
| Net Profit | 168.02 M | 28.51 M | -237.89 M | -291.75 M |
| EPS in Rs | 1.12 | 0.19 | -1.59 | -1.95 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 258.34 M | 448.53 M | 629.6 M | 480.85 M |
| Total Liabilities | 197.33 M | 580.52 M | 823.03 M | 618.26 M |
| Equity | 61.01 M | -131.99 M | -193.43 M | -137.42 M |
| Current Assets | 206.71 M | 341.58 M | 475.63 M | 381.23 M |
| Current Liabilities | 141.88 M | 282.98 M | 331.77 M | 138.69 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -138.51 M | -20.44 M | -174.88 M | -241.12 M |
| Investing CF | 375.09 M | 230.32 M | 144.64 M | -166.85 M |
| Financing CF | -273.7 M | -186.97 M | 69.6 M | 54.33 M |
| Free CF | -138.51 M | -20.44 M | -174.88 M | -241.12 M |
| Capex | — | — | -0.29 M | -2.04 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -89.74% | 21.89% | — | — |
| Earnings Growth % | 111.98% | 18.46% | — | — |
| Profit Margin % | 108.03% | -92.48% | -138.24% | — |
| Operating Margin % | -756.58% | -78.99% | -121.72% | — |
| Gross Margin % | 66.93% | 38.19% | 66.79% | — |
| EBITDA Margin % | -755.56% | -75.39% | -121.1% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.